We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) Metformin-Mepha metformin hydrochloride 1000mg film-coated tablets (Switzerland)
Section 19A approved medicine
(Approval lapsed) Metformin-Mepha metformin hydrochloride 1000mg film-coated tablets (Switzerland)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Expired
Medicines in short supply/unavailable
DIAFORMIN 1000 metformin hydrochloride 1000 mg tablet blister pack - ARTG 82207
FORMET 1000 metformin hydrochloride 1000mg tablet bottle - ARTG 91112
FORMET 1000 metformin hydrochloride 1000mg tablet blister pack - ARTG 91113
METFORMIN GH metformin hydrochloride 1000 mg tablet blister pack - ARTG 284975
METFORMIN SANDOZ metformin hydrochloride 1000 mg tablet blister pack - ARTG 292865
DIAFORMIN VIATRIS metformin hydrochloride 1000mg film-coated tablet blister pack - ARTG 206735
FORMET 1000 metformin hydrochloride 1000mg tablet bottle - ARTG 91112
FORMET 1000 metformin hydrochloride 1000mg tablet blister pack - ARTG 91113
METFORMIN GH metformin hydrochloride 1000 mg tablet blister pack - ARTG 284975
METFORMIN SANDOZ metformin hydrochloride 1000 mg tablet blister pack - ARTG 292865
DIAFORMIN VIATRIS metformin hydrochloride 1000mg film-coated tablet blister pack - ARTG 206735
Indication(s)
Metformin is indicated in the treatment of type 2 diabetes mellitus in adults, children from 10 years of age and adolescents, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
For adult patients, metformin may be used as initial treatment or in sulfonylurea failures either alone or in combination with a sulfonylurea and other oral agents or as adjuvant therapy in insulin requiring type 2 diabetes.
Images
